Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Cardiac Arrhythmia
Interventions: Osteopathic Manipulative Treatment, Light Touch Therapy; Procedure
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Glen Head, New York

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Paclitaxel; Drug
Lead sponsor: Baker Norton Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
Interventions: Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography, Telotristat Etiprate; Other · Procedure · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer, Cardiotoxicity
Interventions: antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers; Other · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Healthy Participants
Interventions: Afimetoran, Phenytoin, Midazolam; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteer
Interventions: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions: Ketorolac Tromethamine 30 MG/ML, Placebos; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pelvic Pain, Endometriosis
Interventions: Metformin Hydrochloride, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Desvenlafaxine Succinate Sustained Release, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostatic Neoplasms
Interventions: MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Fluconazole, Quinidine, EDP-305; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Health Volunteers
Interventions: CTP-543, Fluconazole; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Inosine; Drug
Lead sponsor: Michael Alan Schwarzschild; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Cervical Pain
Interventions: Yoga Group Exercise, Pilates Group Mat Exercise; Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Bloomfield Hills, Michigan • Detroit, Michigan • Novi, Michigan + 1 more

Conditions: Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Interventions: Colchicine, Diltiazem ER; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Alcohol Dependence, Alcohol Use Disorder
Interventions: XR-NTX+CM (Extended-Release Naltrexone plus Care Management); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: Blood Pressure, Electroconvulsive Therapy
Interventions: Alfentanil, Placebos; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: bosutinib or bosutinib + aprepitant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Alzheimer Disease
Interventions: Dexmedetomidine, Dexmedetomidine and Midodrine, Placebo; Drug · Other
Lead sponsor: Applied Cognition; Industry
Eligibility: 55 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Stanford, California • Spokane, Washington

Conditions: Human Immunodeficiency Virus Positive or Negative
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adderall, PTSD, Post Traumatic Stress Disorder
Interventions: Placebo, Adderall; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
Interventions: LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Little Rock, Arkansas • Garden Grove, California • Orange, California + 6 more

Conditions: Sickle Cell Disease
Interventions: Oxbryta® (voxelotor) 500mg Tablets; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 4 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • La Jolla, California + 24 more

Search by objective public record fields.

Effects of Osteopathic Manipulative Therapy on Arrhythmias

Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

A Study of Blood Pressure Control During Cancer Treatment

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

IV Ketorolac on Platelet Function Post-Cesarean Delivery

Glycemic Regulation as Endometriosis Adjunct Treatment

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

A Food-Drug Interaction Study of Serum Urate After Oral Inosine

Effect of Group Pilates and Yoga Exercise Classes for Chronic Cervical Pain

Drug-Drug Interaction Study Between Colchicine and Diltiazem ER

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Pre-medication With Alfentanil vs Placebo During ECT

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

Pharmacological Enhancement of Glymphatic Function in Humans

Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs

Effects of Stimulant Medications in PTSD

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD